Your browser doesn't support javascript.
loading
Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.
Guttman-Yassky, Emma; Del Duca, Ester; Da Rosa, Joel Correa; Bar, Jonathan; Ezzedine, Khaled; Ye, Zhan; He, Wen; Hyde, Craig; Hassan-Zahraee, Mina; Yamaguchi, Yuji; Peeva, Elena.
Afiliación
  • Guttman-Yassky E; Department of Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, NY. Electronic address: emma.guttman@mountsinai.org.
  • Del Duca E; Department of Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, NY.
  • Da Rosa JC; Department of Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, NY.
  • Bar J; Department of Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, NY; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Ezzedine K; Hôpital Henri Mondor and Université Paris-Est Créteil, EpiDermE-Epidemiology in Dermatology and Evaluation of Therapeutics, Creteil, France.
  • Ye Z; Pfizer, Cambridge, Mass.
  • He W; Pfizer, Cambridge, Mass.
  • Hyde C; Pfizer, Cambridge, Mass.
  • Hassan-Zahraee M; Pfizer, Cambridge, Mass.
  • Yamaguchi Y; Pfizer, Collegeville, Pa.
  • Peeva E; Pfizer, Cambridge, Mass.
J Allergy Clin Immunol ; 153(1): 161-172.e8, 2024 01.
Article en En | MEDLINE | ID: mdl-37777018

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vitíligo Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vitíligo Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2024 Tipo del documento: Article